Early Lactate Clearance Rate in Sepsis
Monitoring and Guidance of Early Lactate Clearance Rate in Patients With Sepsis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Fei Tong, Dr.
- Phone Number: +8615803210603
- Email: tongfei168@163.com
Study Contact Backup
- Name: Jiangqing Xu, Dr.
- Phone Number: +8615732193221
- Email: jq745790350@163.com
Study Locations
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- Recruiting
- The Second Hospital of Hebei Medical University
-
Contact:
- Fei Tong, Dr.
- Phone Number: +8615803210603
- Email: tongfei168@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients whose blood lactate level reached or exceeded 2.0 mEq / L
Exclusion Criteria:
- Incomplete clinical data
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
lactate group
Lactate early guide resuscitation
|
Lactate clearance rate was monitored within 6 hours after admission
|
|
control group
early guide resuscitation without lactate
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In-hospital 60days mortality
Time Frame: In-hospital 60 days
|
In-hospital up to 60 days mortality of sepsis
|
In-hospital 60 days
|
|
ICU mortality
Time Frame: up to 30 days
|
ICU up to 30 days mortality of sepsis
|
up to 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 78247891400
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.